A5024346307- Transgenic Plants and Applications
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Toxin Mechanisms and Immunotoxins
- CRISPR and Genetic Engineering
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Glioma Diagnosis and Treatment
- Pregnancy and Medication Impact
- Plant tissue culture and regeneration
- Microbial Inactivation Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Reproductive Health and Contraception
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Reproductive System and Pregnancy
- Long-Term Effects of COVID-19
- Uterine Myomas and Treatments
- Food Allergy and Anaphylaxis Research
Owensboro Health
2023
Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of SARS-CoV-2 receptor-binding domain (RBD) spike glycoprotein (S) fused human IgG1 Fc (CoV-RBD121) and conjugated modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound host receptor ACE2 monoclonal antibody CR3022, neutralizing that blocks S binding ACE2. The...
ABSTRACT Recent incidents in the United States and abroad have heightened concerns about use of ricin toxin as a bioterrorism agent. In this study, we produced, using robust plant-based platform, four chimeric toxin-neutralizing monoclonal antibodies that were then evaluated for ability to passively protect mice from lethal-dose challenge. The most effective antibody, c-PB10, was further therapeutic following exposure by injection inhalation.
With an unplanned pregnancy rate of 50% or more in many countries, there is urgent need for contraceptives that are accessible and acceptable. To meet the growing demand new contraceptives, ZabBio developed ZB-06, a vaginal film containing HC4-N, human contraceptive antibody inactivates sperm.
The ongoing SARS-CoV-2 coronavirus pandemic of 2020–2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on Nicotiana benthamiana produced mAb therapeutics with high batch-to-batch reproducibility and flexibility, enabling production 19 different mAbs sufficient purity safety clinical application(s). With single run, impurities were effectively removed representative product (the ZMapp component...
Significance Nearly half of all pregnancies in the United States are unintended due to millions women avoiding available hormonal contraceptive methods as a result real and/or perceived side effects associated with use exogenous hormones. Topical vaginal delivery antisperm monoclonal antibodies that could agglutinate sperm into clusters too large penetrate mucus and prevent from reaching egg represents potentially safe potent mechanism for nonhormonal contraception. We report here...
We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain spike glycoprotein fused human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is stable for up 12 months at 2-8 or 22-28 °C. Here, we showed that this induces neutralizing response K18-hACE2 mice. Furthermore, demonstrated immunization protects from virus-associated mortality symptomatic disease. Our...
Abstract Non-hormonal products for on-demand contraception are a global health technology gap, motivating us to pursue the use of sperm-binding monoclonal antibodies as strategy enable safe, effective, desirable, contraception. Here, using cGMP-compliant Nicotiana-expression system, we produce an ultra-potent IgG antibody possessing 6 Fab arms per molecule that bind well-established contraceptive antigen target, CD52g. We term this hexavalent “Fab-IgG-Fab” (FIF) reflect its molecular...